Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: "Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]. | Available online http ccforum.eom content 6 4 349 Research Quality of life effects of antithrombin III in sepsis survivors results from the KyberSept trial ISRCTN22931023 Dale Rublee1 Steven M Opal2 Wolfgang Schramm3 Heinz-Otto Keinecke4 and Sigurd Knaub5 Director Outcomes Research Aventis Behring L.L.C. King of Prussia Pennsylvania USA 2Professor of Medicine Brown University Medical School Infectious Disease Division Pawtucket Rhode Island 3Head Department of Hematology Ludwig-Maximillians-University Klinikum Innenstadt Munich Germany 4Biostatistician Aventis Behring GmbH Marburg Germany 5Director Hemophilia Critical Care Aventis Behring GmbH Marburg Germany Correspondence Dale Rublee dale.rublee@aventis.com Received 13 May 2002 Revisions requested 21 May 2002 Revisions received 24 May 2002 Accepted 27 May 2002 Published 24 June 2002 Critical Care 2002 6 349-356 This article is online at http ccforum.com content 6 4 349 2002 Rublee et al. licensee BioMed Central Ltd Print ISSN 1364-8535 Online ISSN 1466-609X Abstract Introduction Treatment of sepsis is aimed at increasing both the duration and quality of survival. A long-term focus on quality of life QoL in clinical trial evaluations of sepsis care should be a priority. Method QoL data were used to evaluate the effects of intravenous antithrombin III treatment for severe sepsis measured for up to 90 days during the follow-up phase of the KyberSept phase III clinical trial. A visual analog scale and a Karnofsky scale were used to measure physical psychologic and social QoL at regular intervals. Changes from baseline between placebo and antithrombin III groups were assessed using Wilcoxon statistical tests with additional analyses by severity of illness and admitting diagnosis. Results Among all sepsis survivors in the trial there was a significant advantage on some attributes of QoL in the antithrombin III subgroup of patients who did not receive heparin as compared with the corresponding placebo group. Discussion